Form 4: Altimmune CEO, Vipin K. Garg, Reports Stock Transactions Following Vesting of Restricted Stock Units and Grant of Stock Options

Altimmune's CEO, Vipin K. Garg, has reported the vesting of restricted stock units and the grant of new stock options, resulting in changes to his beneficial ownership of the company's stock.

Summary

• Vipin K. Garg, the President and CEO of Altimmune, Inc., reported transactions related to his beneficial ownership of the company's stock on January 25, 2025 and January 27, 2025.
• On January 25, 2025, 42,050 restricted stock units (RSUs) vested, converting into common stock.
• A portion of the vested shares, 18,157, were surrendered to cover taxes at a price of $6.98 per share.
• Following these transactions, Mr. Garg directly owns 315,921 shares of common stock.
• On January 27, 2025, Mr. Garg was granted 477,500 stock options with an exercise price of $7.00.
• Additionally, 164,800 new restricted stock units were granted on January 27, 2025.
• The stock options vest over time, with 25% vesting on January 27, 2026, and the remaining 75% vesting monthly over the following 36 months.
• The new RSUs vest in equal annual installments over four years starting January 27, 2025.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and does not contain any negative news. The vesting of RSUs and granting of stock options are generally positive for aligning management with shareholder interests. The sale of shares to cover taxes is a neutral event.

Positives

• The vesting of restricted stock units and the granting of stock options are standard forms of executive compensation.
• The vesting schedule of the stock options and RSUs aligns with long-term performance incentives.

Negatives

• The sale of shares to cover taxes resulted in a reduction of Mr. Garg's direct shareholdings.

Risks

• The value of the stock options is dependent on the future performance of Altimmune's stock price.
• The vesting of the stock options and RSUs is contingent on Mr. Garg's continued service with the company.

Future Outlook

The document does not contain any forward-looking statements about the company's future performance, but it does outline the vesting schedule for the granted stock options and restricted stock units.

Industry Context

This type of filing is standard for publicly traded companies and reflects routine executive compensation practices. The vesting of stock options and RSUs is a common way to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• The vesting schedules for the stock options and RSUs are typical for executive compensation packages in the biotechnology industry.
• Companies like Moderna and BioNTech also use stock options and RSUs as part of their executive compensation packages, with similar vesting periods.
• The exercise price of $7.00 for the stock options is a common practice, often set at or near the market price at the time of grant.

Stakeholder Impact

• The vesting of RSUs and granting of stock options may have a minor dilutive effect on existing shareholders.
• The transactions are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Altimmune, Vipin K. Garg, stock options, restricted stock units, executive compensation, beneficial ownership, stock vesting, SEC Form 4